Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review

References

• Soriano JB, Kendrick PJ, Paulson KR; GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Available from: http://www.goldcopd.com. Accessed July 19, 2021.
   Google Scholar
• Martin C, Frija J, Burgel P-R. Dysfunctional lung anatomy and small airways degeneration in COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:7–13.
   PubMed Web of Science ®Google Scholar
• Hogg JC, McDonough JE, Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013;143(5):1436–1443. doi:10.1378/chest.12-1766
   PubMed Web of Science ®Google Scholar
• Martin C, Frija-Masson J, Burgel P-R. Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs. 2014;74(10):1073–1089. doi:10.1007/s40265-014-0235-3
   PubMed Web of Science ®Google Scholar
• Hogg JC, Paré PD, Hackett T-L. The Contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev. 2017;97(2):529–552. doi:10.1152/physrev.00025.2015
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015–1026. doi:10.1016/S0140-6736(11)60988-4
   PubMed Web of Science ®Google Scholar
• Hou J, Sun Y. Role of regulatory t cells in disturbed immune homeostasis in patients with chronic obstructive pulmonary disease. Front Immunol. 2020;11:723. doi:10.3389/fimmu.2020.00723
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2). doi:10.1183/13993003.00651-2019
   Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al.; ETHOS investigators. Reduced all-cause mortality in the ethos trial of budesonide/glycopyrrolate/formoterol for COPD: a Randomized, Double-Blind, Multi-Center Parallel-Group Study. Am J Respir Crit Care Med. 2021 Mar 1;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955. doi:10.1164/rccm.200906-0876OC
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338. doi:10.1164/rccm.200712-1869OC
   PubMed Web of Science ®Google Scholar
• Boardman C, Chachi L, Gavrila A, et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther. 2014;29(2):129–143. doi:10.1016/j.pupt.2014.08.008
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645. doi:10.1016/j.jaci.2012.12.1564
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2016;37:1–8. doi:10.1016/j.pupt.2016.01.002
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92–100. doi:10.4104/pcrj.2012.00092
   PubMedGoogle Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385(9979):1789–1798. doi:10.1016/S0140-6736(15)60693-6
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351. doi:10.1183/13993003.00351-2020.
   Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Mei D, Tan WSD, Wong WSF. Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD. Curr Opin Pharmacol. 2019;46:73–81. doi:10.1016/j.coph.2019.04.010
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JAJW, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. doi:10.1016/S2213-2600(14)70019-0
   PubMed Web of Science ®Google Scholar
• Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278(25):1355–1360. doi:10.1056/NEJM196806202782501
   PubMed Web of Science ®Google Scholar
• Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72(3):1016–1023. doi:10.1152/jappl.1992.72.3.1016
   PubMed Web of Science ®Google Scholar
• Young AL, Bragman FJS, Rangelov B, et al.; COPDGene Investigators. Disease progression modeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(3):294–302. doi:10.1164/rccm.201908-1600OC
   PubMed Web of Science ®Google Scholar
• Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol. 1993;264:L458–464.
   PubMedGoogle Scholar
• Dent G, Poppe H, Egerland J, et al. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998;11(1):13–21. doi:10.1006/pupt.1998.0111
   PubMed Web of Science ®Google Scholar
• Abbott-Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol. 2014;114(5):365–376. doi:10.1111/bcpt.12209
   PubMed Web of Science ®Google Scholar
• Fertig BA, Baillie GS. PDE4-mediated cAMP signalling. J Cardiovasc Dev Dis. 2018;5(1):8. doi:10.3390/jcdd5010008
   PubMed Web of Science ®Google Scholar
• Brescia M, Zaccolo M. Modulation of compartmentalised cyclic nucleotide signalling via local inhibition of phosphodiesterase activity. Int J Mol Sci. 2016;17(10):1672.
   PubMed Web of Science ®Google Scholar
• Beavo JA, Brunton LL. Cyclic nucleotide research – still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3(9):710–718. doi:10.1038/nrm911
   PubMed Web of Science ®Google Scholar
• Zuo H, Cattani-Cavalieri I, Valença SS, Musheshe N, Schmidt M. Function of cAMP scaffolds in obstructive lung disease: focus on epithelial-to-mesenchymal transition and oxidative stress. Br J Pharmacol. 2019;176(14):2402–2415. doi:10.1111/bph.14605
   PubMed Web of Science ®Google Scholar
• Zuo H, Han B, Poppinga WJ, et al. Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells. Br J Pharmacol. 2018;175(14):2988–3006. doi:10.1111/bph.14347
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs. 2014;74(17):1983–1992.
   PubMed Web of Science ®Google Scholar
• Spina D, Page CP. Xanthines and phosphodiesterase inhibitors. Handb Exp Pharmacol. 2017;237:63–91.
   PubMedGoogle Scholar
• Milara J, Armengot M, Bañuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. Br J Pharmacol. 2012;166(8):2243–2262. doi:10.1111/j.1476-5381.2012.01929.x
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019;28(10):827–833. doi:10.1080/13543784.2019.1661990
   PubMed Web of Science ®Google Scholar
• Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br J Pharmacol. 2016;173(15):2335–2351. doi:10.1111/bph.13512
   PubMed Web of Science ®Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414–423. doi:10.1124/jpet.113.204644
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23. doi:10.1016/j.pupt.2015.03.007
   PubMed Web of Science ®Google Scholar
• Barber R, Baillie GS, Bergmann R, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L332–343. doi:10.1152/ajplung.00384.2003
   PubMed Web of Science ®Google Scholar
• Leclerc O, Lagente V, Planquois J-M, et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J. 2006;27(6):1102–1109. doi:10.1183/09031936.06.00076905
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005;172(7):848–853. doi:10.1164/rccm.200411-1549OC
   PubMed Web of Science ®Google Scholar
• Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther. 2003;307(1):373–385. doi:10.1124/jpet.103.053942
   PubMed Web of Science ®Google Scholar
• Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci. 2004;25(8):430–436. doi:10.1016/j.tips.2004.06.008
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, Page CP. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther. 2005;18(2):93–101. doi:10.1016/j.pupt.2004.10.001
   PubMed Web of Science ®Google Scholar
• Lagente V, Martin-Chouly C, Boichot E, Martins MA, Silva PMR. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz. 2005;100(Suppl 1):131–136. doi:10.1590/S0074-02762005000900023
   PubMed Web of Science ®Google Scholar
• Sousa LP, Lopes F, Silva DM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol. 2010;87:895–904.
   PubMed Web of Science ®Google Scholar
• Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions. 1993;39(S1):C77–C79. doi:10.1007/BF01972726
   PubMedGoogle Scholar
• Jin S-LC, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99(11):7628–7633. doi:10.1073/pnas.122041599
   PubMed Web of Science ®Google Scholar
• Gantner F, Schudt C, Wendel A, Hatzelmann A. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function. Pulm Pharmacol Ther. 1999;12(6):377–386. doi:10.1006/pupt.1999.0220
   PubMed Web of Science ®Google Scholar
• Tannheimer SL, Sorensen EA, Haran AC, Mansfield CN, Wright CD, Salmon M. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. Pulm Pharmacol Ther. 2012;25(2):178–184. doi:10.1016/j.pupt.2012.01.003
   PubMed Web of Science ®Google Scholar
• Mata M, Martinez I, Melero JA, Tenor H, Cortijo J. Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells. PLoS One. 2013;8(7):e69670. doi:10.1371/journal.pone.0069670
   PubMed Web of Science ®Google Scholar
• Turner MJ, Dauletbaev N, Lands LC, Hanrahan JW. The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4. J Pharmacol Exp Ther. 2020;375(3):414–429. doi:10.1124/jpet.120.000080
   PubMed Web of Science ®Google Scholar
• Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233–2247. doi:10.1056/NEJMra0910061
   PubMed Web of Science ®Google Scholar
• Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol. 2013;305(8):L530–541. doi:10.1152/ajplung.00039.2013
   PubMed Web of Science ®Google Scholar
• Liu S, Veilleux A, Zhang L, et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005;314(2):846–854. doi:10.1124/jpet.105.083519
   PubMed Web of Science ®Google Scholar
• Kelley TJ, Al-Nakkash L, Drumm ML. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol. 1995;13(6):657–664. doi:10.1165/ajrcmb.13.6.7576703
   PubMed Web of Science ®Google Scholar
• Lambert JA, Raju SV, Tang LP, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2014;50(3):549–558. doi:10.1165/rcmb.2013-0228OC
   PubMed Web of Science ®Google Scholar
• Blanchard E, Zlock L, Lao A, et al. Anchored PDE4 regulates chloride conductance in wild-type and ΔF508-CFTR human airway epithelia. FASEB J. 2014;28(2):791–801. doi:10.1096/fj.13-240861
   PubMed Web of Science ®Google Scholar
• Workman AD, Cohen NA. The effect of drugs and other compounds on the ciliary beat frequency of human respiratory epithelium. Am J Rhinol Allergy. 2014;28(6):454–464. doi:10.2500/ajra.2014.28.4092
   PubMed Web of Science ®Google Scholar
• Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;9:CD002309.
   PubMedGoogle Scholar
• Shen L-F, Lv X-D, Chen W-Y, Yang Q, Fang Z-X, Lu W-F. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ir J Med Sci. 2018;187(3):731–738. doi:10.1007/s11845-018-1738-9
   PubMed Web of Science ®Google Scholar
• Rhee CK, Kim DK. Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease. Korean J Intern Med. 2020;35(2):276–283. doi:10.3904/kjim.2020.035
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi:10.1016/S2213-2600(13)70187-5
   PubMed Web of Science ®Google Scholar
• Singh D, Abbott-Banner K, Bengtsson T, Newman K. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-2018
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C. An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. Eur Respir J. 2018;52(5):1801675. doi:10.1183/13993003.01675-2018
   PubMed Web of Science ®Google Scholar
• Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020;21(47). doi:10.1186/s12931-020-1307-4
   Web of Science ®Google Scholar
• Watz H, Rickard K, Rheault T, Bengtsson T, Singh D. Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD - A detailed analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2199–2206. doi:10.2147/COPD.S263025
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Kerwin EM, Rheault T, Bengtsson T, Rickard K. A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy. Int J Chron Obstruct Pulmon Dis. 2021;16:1137–1148. doi:10.2147/COPD.S307160
   PubMed Web of Science ®Google Scholar
• Bjermer L, Abbott-Banner K, Newman K. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm Pharmacol Ther. 2019;58:101814. doi:10.1016/j.pupt.2019.101814
   PubMed Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–1087. doi:10.1136/thx.2006.075937
   PubMed Web of Science ®Google Scholar